This invention relates to novel heterocycles which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), also referred to as 11 CBy, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in medicines. Compounds of the invention have the formula:
[EN] HETEROCYCLIC MCHR1 ANTAGONISTS<br/>[FR] ANTAGONISTES HETEROCYCLIQUES DE MCHR1
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2004092181A1
公开(公告)日:2004-10-28
This invention relates to novel heterocycles which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), also referred to as 11CBy, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in medicines. Compounds of the invention have formula (I).
Potent, Selective, and Orally Efficacious Antagonists of Melanin-Concentrating Hormone Receptor 1
作者:Francis X. Tavares、Kamal A. Al-Barazanji、Eric C. Bigham、Michael J. Bishop、Christy S. Britt、David L. Carlton、Paul L. Feldman、Aaron S. Goetz、Mary K. Grizzle、Yu C. Guo、Anthony L. Handlon、Donald L. Hertzog、Diane M. Ignar、Daniel G. Lang、Ronda J. Ott、Andrew J. Peat、Hui-Qiang Zhou
DOI:10.1021/jm060572f
日期:2006.11.30
The high expression of MCH in the hypothalamus with the lean hypophagic phenotype coupled with increased resting metabolic rate and resistance to high fat diet-induced obesity of MCH KO mice has spurred considerable efforts to develop small molecule MCHR1 antagonists. Starting from a lead thienopyrimidinone series, structure-activity studies at the 3- and 6-positions of the thienopyrimidinone core afforded potent and selective MCHR1 antagonists with representative examples having suitable pharmacokinetic properties. Based on structure-activity relationships, a structural model for MCHR1 was constructed to explain the binding mode of these antagonists. In general, a good correlation was observed between pK(a)s and activity in the right-hand side of the template, with Asp123 playing an important role in the enhancement of binding affinity. A representative example when evaluated chronically in diet-induced obese mice resulted in good weight loss effects. These antagonists provide a viable lead series in the discovery of new therapies for the treatment of obesity.
A Novel One-Pot Synthesis of N-Substituted Thieno[3,2-d]pyrimidin-4(3H)-ones
作者:Andrew J. Peat、Paul L. Feldman、Dulce Garrido、Yu C. Guo、Donald L. Hertzog
DOI:10.3987/com-06-s(w)31
日期:——
A novel synthetic route for the construction of thieno[3,2-d]pyrimidin-4(3H)-ones has been developed with the key step involving an AlMe 3 -promoted ester-to-amide conversion. The yields within this initial set of analogs are comparable to those obtained via our previously reported routes and in at least one case far superior, thus serving to compliment other approaches to this useful chemical scaffold